{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:13:59Z","timestamp":1778721239900,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Extraprostatic extension (EPE) significantly impacts surgical planning for prostate cancer (PCa) patients, influencing nerve-sparing surgery and neoadjuvant therapy decisions. However, Likert-scale-based radiological (r)EPE assessment lacks sufficient diagnostic accuracy for reliable clinical decision-making. Therefore, the aim was to evaluate rEPE scoring alongside clinical parameters to develop a clinically feasible decision tree for preoperative risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center study included 429 consecutive PCa patients undergoing radical prostatectomy between January 2012 and October 2018. All patients underwent multiparametric MRI with PI-RADS scoring and rEPE grading (grades 0\u20133). Clinical parameters included PSA density (PSAD) and ISUP grade group (GG) at biopsy. Univariate and multivariate logistic regression identified predictors of EPE. A clinical decision tree was developed using binary classification to stratify patients into risk groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      EPE was confirmed in 145 patients (33.8%). Multivariate analysis identified rEPE grade (OR 2.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and GG at biopsy (OR 1.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) as independent predictors. The decision tree assigned 48% of patients to the high-risk (rEPE grade 3: 89% EPE risk) and low-risk group (rEPE\u2009&lt;\u20093\u2009+\u2009PSAD\u2009&lt;\u20090.2\u2009ng\/mL\u00b2\u2009+\u2009GG\u2009&lt;\u20094: 13% EPE risk), while 52% showed intermediate risk (28\u201345% EPE risk).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed decision tree combining MRI-derived rEPE grading, PSAD, and biopsy GG enables reliable identification of patients at high and low risk for EPE. This tool supports informed decision-making regarding nerve-sparing surgery and neoadjuvant therapy, potentially contributing to personalized treatment planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>Decision tree combining routine MRI-based and clinical markers reliably stratifies prostate cancer patients into high-risk and low-risk groups for EPE, supporting personalized surgical planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>EPE affects surgical planning decisions in prostate cancer patients.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Combining EPE grade at MRI, PSAD, and biopsy grade improves risk stratification.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The developed decision tree reliably stratified every second patient into distinct EPE-risk groups, potentially improving personalized surgical planning.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02305-5","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:47:09Z","timestamp":1778719629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imaging-based clinical decision tree enables risk stratification of extraprostatic extension before radical prostatectomy in prostate cancer patients"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-4758","authenticated-orcid":false,"given":"Charlie A.","family":"Hamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"R\u00fcterhenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg L.","family":"Baumg\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherina","family":"Mayerosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Lindholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick L.","family":"Beetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Penzkofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2305_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J et al (2024) The lancet commission on prostate cancer: planning for the surge in cases. Lancet 403:1683\u20131722","journal-title":"Lancet"},{"key":"2305_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm CA, Asbach P, P\u00f6hlmann A et al (2025) Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer. JAMA Oncol 11:145\u2013153","journal-title":"JAMA Oncol"},{"key":"2305_CR3","doi-asserted-by":"publisher","first-page":"110228","DOI":"10.1016\/j.ejrad.2022.110228","volume":"149","author":"U Asfuro\u011flu","year":"2022","unstructured":"Asfuro\u011flu U, Asfuro\u011flu BB, \u00d6zer H et al (2022) Which one is better for predicting extraprostatic extension on multiparametric MRI: ESUR score, Likert scale, tumor contact length, or EPE grade? Eur J Radiol 149:110228","journal-title":"Eur J Radiol"},{"key":"2305_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020192133","volume":"296","author":"KJ Park","year":"2020","unstructured":"Park KJ, Kim MH, Kim JK (2020) Extraprostatic tumor extension: comparison of preoperative multiparametric mri criteria and histopathologic correlation after radical prostatectomy. Radiology 296:87\u201395","journal-title":"Radiology"},{"key":"2305_CR5","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1007\/s00330-022-08595-9","volume":"32","author":"M Gatti","year":"2022","unstructured":"Gatti M, Faletti R, Gentile F et al (2022) mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. Eur Radiol 32:4942\u20134953","journal-title":"Eur Radiol"},{"key":"2305_CR6","doi-asserted-by":"publisher","first-page":"112363","DOI":"10.1016\/j.ejrad.2025.112363","volume":"191","author":"G Agrotis","year":"2025","unstructured":"Agrotis G, Woo S, J\u00e4derling F et al (2025) Radiological T-staging in prostate cancer: towards a universal MRI-based scoring system. Eur J Radiol 191:112363","journal-title":"Eur J Radiol"},{"key":"2305_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1148\/radiol.2018181278","volume":"290","author":"S Mehralivand","year":"2019","unstructured":"Mehralivand S, Shih JH, Harmon S et al (2019) A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology 290:709\u2013719","journal-title":"Radiology"},{"key":"2305_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/bco2.115","volume":"3","author":"AN Vis","year":"2022","unstructured":"Vis AN, van den Bergh R, van der Poel HG et al (2022) Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy. BJUI Compass 3:6\u201318","journal-title":"BJUI Compass"},{"key":"2305_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2013.07.039","volume":"65","author":"O Yossepowitch","year":"2014","unstructured":"Yossepowitch O, Briganti A, Eastham JA et al (2014) Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 65:303\u2013313","journal-title":"Eur Urol"},{"key":"2305_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton CAF, Lin X, Hanks GE et al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98:296\u2013303","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2305_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1148\/radiol.210875","volume":"302","author":"AG Wibmer","year":"2022","unstructured":"Wibmer AG, Nikolovski I, Chaim J et al (2022) Local extent of prostate cancer at MRI versus prostatectomy histopathology: associations with long-term oncologic outcomes. Radiology 302:595\u2013602","journal-title":"Radiology"},{"key":"2305_CR12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/j.1464-410X.2009.08688.x","volume":"104","author":"G Godoy","year":"2009","unstructured":"Godoy G, Tareen BU, Lepor H (2009) Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int 104:1610\u20131614","journal-title":"BJU Int"},{"key":"2305_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0022-5347(17)36587-4","volume":"148","author":"MA Rosen","year":"1992","unstructured":"Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT (1992) Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148:331\u2013337","journal-title":"J Urol"},{"key":"2305_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13244-023-01516-4","volume":"14","author":"L Xu","year":"2023","unstructured":"Xu L, Zhang G, Zhang D et al (2023) An MRI-based grading system for preoperative risk estimation of positive surgical margin after radical prostatectomy. Insights Imaging 14:178","journal-title":"Insights Imaging"},{"key":"2305_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70:233\u2013245","journal-title":"Eur Urol"},{"key":"2305_CR16","doi-asserted-by":"publisher","first-page":"e222276","DOI":"10.1148\/radiol.222276","volume":"307","author":"CA Hamm","year":"2023","unstructured":"Hamm CA, Baumg\u00e4rtner GL, Biessmann F et al (2023) Interactive explainable deep learning model informs prostate cancer diagnosis at MRI. Radiology 307:e222276","journal-title":"Radiology"},{"key":"2305_CR17","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1007\/s00330-024-10700-z","volume":"34","author":"CA Hamm","year":"2024","unstructured":"Hamm CA, Baumg\u00e4rtner GL, Padhani AR et al (2024) Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies. Eur Radiol 34:6229\u20136240","journal-title":"Eur Radiol"},{"key":"2305_CR18","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Isra\u00ebl B, Tummers M et al (2020) ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol 30:5404\u20135416","journal-title":"Eur Radiol"},{"key":"2305_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340\u2013351","journal-title":"Eur Urol"},{"key":"2305_CR20","first-page":"763","volume":"193","author":"T Franiel","year":"2021","unstructured":"Franiel T, Asbach P, Beyersdorff D et al (2021) mpMRI of the prostate (MR-prostatography): updated recommendations of the DRG and BDR on patient preparation and scanning protocol. Rofo 193:763\u2013777","journal-title":"Rofo"},{"key":"2305_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.juro.2018.05.003","volume":"200","author":"SL Hofbauer","year":"2018","unstructured":"Hofbauer SL, Maxeiner A, Kittner B et al (2018) Validation of prostate imaging reporting and data system version 2 for the detection of prostate cancer. J Urol 200:767\u2013773","journal-title":"J Urol"},{"key":"2305_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh R, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243\u2013262","journal-title":"Eur Urol"},{"key":"2305_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/modpathol.2010.158","volume":"24","author":"C Magi-Galluzzi","year":"2011","unstructured":"Magi-Galluzzi C, Evans AJ, Delahunt B et al (2011) International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 24:26\u201338","journal-title":"Mod Pathol"},{"key":"2305_CR24","doi-asserted-by":"crossref","unstructured":"Breiman L, Friedman J, Olshen RA, Stone CJ (2017) Classification and regression trees. Chapman and Hall\/CRC, New York","DOI":"10.1201\/9781315139470"},{"key":"2305_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.euf.2018.11.004","volume":"6","author":"J Nyarangi-Dix","year":"2020","unstructured":"Nyarangi-Dix J, Wiesenfarth M, Bonekamp D et al (2020) Combined clinical parameters and multiparametric magnetic resonance imaging for the prediction of extraprostatic disease\u2014a risk model for patient-tailored risk stratification when planning radical prostatectomy. Eur Urol Focus 6:1205\u20131212","journal-title":"Eur Urol Focus"},{"key":"2305_CR26","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1007\/s00261-025-04948-2","volume":"50","author":"S Woo","year":"2025","unstructured":"Woo S, Freedman D, Becker AS et al (2025) Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET\/CT. Abdom Radiol (NY) 50:5274\u20135282","journal-title":"Abdom Radiol (NY)"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02305-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:47:11Z","timestamp":1778719631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02305-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02305-5","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study complies with the Standards for Reporting of Diagnostic Accuracy guidelines and was approved by the institutional review board of the Charit\u00e9 (EA1\/271\/16 und EA2\/033\/18) with waiver of written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.A.H. receives funding from the Berlin Institute of Health (Digital Clinician Scientist Grant), Siemens Healthineers,\u00a0and the\u00a0German Federal Ministry of Research, Technology and Space (BMFTR) Network of University Medicine 3.0\u00a0(\u201cNUM 3.0\u201d, Grant No. 01KX2524) and previously received seed funding from the University Medicine Greifswald and speaker fees from Siemens Healthineers, Bayer AG, Koelis AG, and Bracco Imaging Deutschland outside the submitted work and is on the advisory board of Lucida Medical. P.A. reported payments from the Professional Association of the German Radiologist (BDR e.\u200aV.) for quality assessment of prostate MRIs and travel funding from the European Society of Radiology (ESR), Deutsche R\u00f6ntgengesellschaft (DRG), Norddeutsche R\u00f6ntgengesellschaft, Kongressverein f\u00fcr Radiologische Diagnostik e. V., Deutsche Gesellschaft f\u00fcr Urologie (DGU) and Int. Cancer Imaging Society (ICIS). Moreover, he is a member of the guideline panel of the German S3 guideline on prostate cancer (delegate of the Professional Association of the German Radiologists (BDR e.\u200aV.; unpaid). T.P. also receives funding from the Berlin Institute of Health (Advanced Clinician Scientist Grant, Platform Grant), the Ministry of Education and Research (BMBF, 01KX2121 (\u201cNUM 2.0\u201d, RACOON), 68GX21001A, 01ZZ2315D,\u00a0\u201cNUM 3.0\u201d, 01KX2524), the German Research Foundation (DFG, SFB 1340\/2), and the European Union (H2020, CHAIMELEON: 952172, DIGITAL, EUCAIM:101100633). Furthermore, T.P. declares relationships with the following companies: research agreements (no personal payments) with AGO, Aprea AB, AR-CAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc.; fees for a book translation (Elsevier B.V.); and fees for speaking engagements (Bayer Healthcare).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}